Studie

Resveratrol for Improved Performance in the Elderly (RIPE) — clinical trial listing

University of Florida

TWO-YEAR RANDOMISED TRIAL COMPARING 300 MG/DAY VS 1,000 MG/DAY VS PLACEBO ON COGNITIVE AND PHYSICAL OUTCOMES IN OLDER ADULTS Tier 3 2010

A rare two-year cognitive-and-physical outcome trial comparing 300 mg and 1,000 mg per dag of resveratrol against placebo in older adults.

StudiedesignTWO-YEAR RANDOMISED TRIAL COMPARING 300 MG/DAY VS 1,000 MG/DAY VS PLACEBO ON COGNITIVE AND PHYSICAL OUTCOMES IN OLDER ADULTS
TierNivå 3, Blandad humana bevis, mekanism trovärdig
År2010
TidskriftClinicalTrials.gov
Publiceradapr 15, 2010
Tillagd i NO1GEVITYjul 1, 2026

RIPE is one of the longer-duration resveratrol trials on record. It compares 300 mg per dag and 1,000 mg per dag against placebo for 24 months, with cognitive and physical performance as primär endpoints, in older adults. We include the ClinicalTrials.gov listing because the full outcome paper has been slow to publish. This is exactly the kind of long-duration, dose-comparison, hard-endpoint trial that could actually settle whether resveratrol does anything meaningful in an aging population. It has not yet done so publicly.

Studie status and outcomes are documented at ClinicalTrials.gov identifier NCT01126229.
Kritikernoter

Results have not yet been published in a peer-reviewed journal in a form that lets us judge effect size.

Läs källan

Citerad av

1 encyklopediartiklar refererar till denna studie.